Testicular cancer types
Most testicular cancers develop from germ cells in the testicles, so they are also called germ cell tumours. There are two main types, seminomas and non-seminomas.
On this page
Germ cell tumours
After surgeons have removed the testicle, the tissue is examined under a microscope. This will help doctors find out the type of testicular cancer you may have.
Most testicular cancers develop from germ cells in the testicles. They are also called germ cell tumours (GCTs). Germ cells in the testicles produce sperm.
There are 2 main types of testicular germ cell cancer:
- seminomas
- non-seminomas.
Sometimes, testicular cancers are a combination of non-seminomas and seminomas. This is also called a mixed germ cell tumour cancer. Testicular cancer is the general term used for all types of testicular cancer.
Seminomas
Seminomas can happen between the ages of 15 and 50. But the average age at diagnosis is 35. About 40 to 45 in 100 (40 to 45%) testicular cancers are seminoma.
Non-seminomas
Non-seminomas usually occur between the ages of 15 and 35. About 40 to 45 in 100 (40 to 45%) testicular cancers are non-seminoma.
Non-seminomas are made of different types of cells. They can be made of just one cell type, or they may be made of a mixture. They include:
- teratomas
- embryonal tumours
- yolk sac tumours
- choriocarcinomas.
We have more information about testicular cancer treatment.
Rarer types
Sometimes, the cancer found in the testicle is not a germ cell tumour, but another type of cancer. These include rare types of cancer called Leydig cell tumours and Sertoli cell tumours. Another rare type of testicular cancer is a type of non-Hodgkin lymphoma.
To find out more about these rarer types of testicular cancer and their treatment, contact our cancer support specialists.
Related pages
About our information
-
References
Below is a sample of the sources used in our testicular cancer information. If you would like more information about the sources we use, please contact us at cancerinformationteam@macmillan.org.uk
The British Association of Urological Surgeons (BAUS) Guidelines on Testicular Cancer. March 2015. Available from: https://www.baus.org.uk/professionals/sections/testicular_cancer.aspx (accessed April 2022).
European Association of Urology (EAU) Guidelines on Testicular Cancer 2022. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Testicular-Cancer-2022.pdf (accessed April 2022).
European Society for Medical Oncology (ESMO). Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Last updated 2022.
European Society for Medical Oncology (ESMO). Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Last updated 2022. Available from: https://www.annalsofoncology.org/article/S0923-7534(22)00007-2/fulltext (accessed April 2022).
-
Reviewers
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Dr Ursula McGovern, Consultant Medical Oncologist.
Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.
The language we use
We want everyone affected by cancer to feel our information is written for them.
We want our information to be as clear as possible. To do this, we try to:
- use plain English
- explain medical words
- use short sentences
- use illustrations to explain text
- structure the information clearly
- make sure important points are clear.
We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.
You can read more about how we produce our information here.
Date reviewed
Our cancer information meets the PIF TICK quality mark.
This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.
How we can help